60
Participants
Start Date
October 1, 2021
Primary Completion Date
September 15, 2022
Study Completion Date
September 15, 2022
PF-06947386
Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
Metronidazole
Metronidazole 0.5 g solution for injection.
Nagoya Ekisaikai Hospital, Nagoya
National Hospital Organization Nagoya Medical Center, Nagoya
National Hospital Organization Toyohashi Medical Center, Toyohashi
Fukuoka Tokushukai Hospital, Kasuga
St.Mary's Hospital, Kurume
Gunma Saiseikai Maebashi Hospital, Maebashi
Saiseikai Maebashi Hospital, Maebashi
Teine Keijinkai Hospital, Sapporo
Tsuchiura Kyodo General Hospital, Tsuchiura
Tsuchiura Kyodo General Hospital, Tsuchiura-shi
National Hospital Organization Kanazawa Medical Center, Kanazawa
Kawasaki Saiwai Hospital, Kawasaki-shi
Sagamihara Kyodo Hospital, Sagamihara
National Hospital Organization Yokohama Medical Center, Yokohama
Suwa Red Cross Hospital, Suwa
National Hospital Organization Nagasaki Medical Center, Ōmura
Nagaoka Chuo General Hospital, Nagaoka
Naha City Hospital, Naha
Rinku General Medical Center, Izumisano
National Hospital Organization Osaka Minami Medical Center, Kawachi-Nagano
Yamanashi Prefectural Central Hospital, Kofu
National Hospital Organization Chiba Medical Center, Chiba
Fukuoka Wajiro Hospital, Fukuoka
National Hospital Organization Kumamoto Medical Center, Kumamoto
National Hospital Organization Kyoto Medical Center, Kyoto
Okayama City General Medical Center Okayama City Hospital, Okayama
Osaka Saiseikai Nakatsu Hospital, Osaka
Toyama University Hospital, Toyama
Yamagata City Hospital Saiseikan, Yamagata
Lead Sponsor
Pfizer
INDUSTRY